Who are Inhaled Long-Acting Muscarinic Antagonist's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug: ipratropium (AtroventTM), Albuterol, ipratropium bromide, solifenacin succinate suspension, Toviaz (Fesoterodine), salbutamol + ipratropium bromide nebules, Solifenacin for 24 weeks.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inhaled-long-acting-muscarinic-antagonist.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Inhaled Long-Acting Muscarinic Antagonist — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inhaled Long-Acting Muscarinic Antagonist (Inhaled Long-Acting Muscarinic Antagonist) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory / Pulmonology.

phase 3 Long-acting muscarinic antagonist (LAMA) M3 muscarinic acetylcholine receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Inhaled Long-Acting Muscarinic Antagonist (Inhaled Long-Acting Muscarinic Antagonist) — Sanofi. Blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion in chronic respiratory diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Inhaled Long-Acting Muscarinic Antagonist TARGET	Inhaled Long-Acting Muscarinic Antagonist	Sanofi	phase 3	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic acetylcholine receptor
Drug: ipratropium (AtroventTM)	Drug: ipratropium (AtroventTM)	AstraZeneca	marketed	Anticholinergic bronchodilator	M3 muscarinic acetylcholine receptor
Albuterol, ipratropium bromide	Albuterol, ipratropium bromide	Children's Hospital of Philadelphia	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor
solifenacin succinate suspension	solifenacin succinate suspension	Astellas Pharma Inc	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Toviaz (Fesoterodine)	Toviaz (Fesoterodine)	Weill Medical College of Cornell University	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
salbutamol + ipratropium bromide nebules	salbutamol + ipratropium bromide nebules	Imperial College London	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium)
Solifenacin for 24 weeks	Solifenacin for 24 weeks	National Taiwan University Hospital	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

GlaxoSmithKline · 9 drugs in this class
AstraZeneca · 3 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Chiesi Farmaceutici S.p.A. · 1 drug in this class
IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
Lupin, Inc. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inhaled Long-Acting Muscarinic Antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/inhaled-long-acting-muscarinic-antagonist. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab